1Nakata K, Zhu YJ, Shin YS, et al. Symposium: diffuse panbronchiolitis in Asia.熊本，第38回日本呼吸器学会总会,1998：103-108．
2Yanagihara K, Kadoto J, Kohno S. Diffuse panbronchiolitis pahtophysiology and treatment mechanisms. Int J Antimicrob Agents, 2001,18 ( Suppl 1) : S83-87.
3Akai S, Okayama H, Shimura S, et al. Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan. Am Rev Respir Dis, 1992, 146 (3): 781-783.
5Kaneko Y,Yanagihara K, Seki M, et al. Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am J Physiol Lung Cell Mol Physiol,2003,285 (4) : L847-853.
6Kamio K, Matsushita I, Hijikata M, et al. Promoter analysis and aberrant expression of MUCSB gene in diffuse panbronchiolitis.Am J Respir Crit Care Med,2005,171(9) :949-957.
7Boat TF,Cheng PW. Biochemistry of mucus:Airway secretion.Fed Proc, 1989,39 (13) : 3067-3074.
8Kim JH, Jung KH, Han JH, et al. Relation of epidermal growth factor receptor expression to mucus hypersecretion in diffuse panbronchiolitis. Chest, 2004,126 (3) : 888-895.
9Shuichi A, Hidenori N, Sumito I, et al. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol,2000,22(1):51-60.
10Keicho N, Tokunaga K, Nakata K, et al. Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis. Am J Respir Crit Care Med, 1998,158(3) : 846-850.
